What’s OpGen, Inc. (OPGN) Upside After Today’s Huge Increase?

OpGen, Inc. (NASDAQ:OPGN) Logo

The stock of OpGen, Inc. (NASDAQ:OPGN) is a huge mover today! The stock increased 14.15% or $0.89 during the last trading session, reaching $7.18. About 75,333 shares traded. OpGen, Inc. (NASDAQ:OPGN) has declined 81.47% since September 11, 2018 and is downtrending. It has underperformed by 81.47% the S&P500.
The move comes after 5 months positive chart setup for the $7.35M company. It was reported on Sep, 11 by Barchart.com. We have $7.75 PT which if reached, will make NASDAQ:OPGN worth $588,160 more.

Analysts await OpGen, Inc. (NASDAQ:OPGN) to report earnings on November, 12. They expect $-2.60 EPS, up 75.47 % or $8.00 from last year’s $-10.6 per share. After $-3.00 actual EPS reported by OpGen, Inc. for the previous quarter, Wall Street now forecasts -13.33 % EPS growth.

More notable recent OpGen, Inc. (NASDAQ:OPGN) news were published by: Bizjournals.com which released: “Germantown biopharma stock on the brink of delisting – Washington Business Journal” on June 03, 2019, also Globenewswire.com with their article: “OpGen Appoints R. Don Elsey to Board of Directors – GlobeNewswire” published on February 25, 2019, Globenewswire.com published: “OpGen Completes Initial FDA 510(k) Submission for its AcuitasĀ® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance – GlobeNewswire” on May 14, 2019. More interesting news about OpGen, Inc. (NASDAQ:OPGN) were released by: Seekingalpha.com and their article: “Opgen up 17% after 1:20 stock split – Seeking Alpha” published on August 30, 2019 as well as Finance.Yahoo.com‘s news article titled: “A Look At Benzinga Pro’s Most-Searched Tickers For June 14 – Yahoo Finance” with publication date: June 14, 2019.

OpGen, Inc., a precision medicine company, engages in developing molecular information services and products to combat infectious diseases in the healthcare industry worldwide. The company has market cap of $7.35 million. The firm utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It currently has negative earnings. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

OpGen, Inc. (NASDAQ:OPGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.